Abstract | BACKGROUND: METHODS: Animals were gavaged with 250 or 500 mg/kg of SBI twice daily for 4 days, before intraperitoneal administration of 200 mg/kg irinotecan. Twice daily gavaging of SBI continued for 6 days post- irinotecan. Animals were monitored for bodyweight changes and incidence of diarrhoea and clinical symptoms of stress. Tissues and blood samples were collected at necropsy 6 h, and 2, 4 and 6 days post- irinotecan. H&E-stained colon and jejunum were analysed for histological damage. RESULTS: The overall incidence, severity and duration of diarrhoea, and clinical symptoms of mucositis were decreased in irinotecan-treated animals that had received SBI. Animals receiving 500 mg/kg SBI also tended to lose less bodyweight than animals treated only with irinotecan (P > 0.10). SBI-gavaged animals had less pronounced irinotecan-induced changes in neutrophil (P = 0.04959) and lymphocyte (P = 0.0035) levels, and lower tissue damage scores than those receiving irinotecan alone (P < 0.0001). CONCLUSIONS: Twice daily oral gavage of SBI was well-tolerated and reduced the incidence, severity and duration of irinotecan-induced mucositis. SBI was associated with less pronounced changes in inflammatory cell levels and tissue damage to colon and jejunum. Ongoing experiments aim to investigate the mechanisms of SBI-associated gastrointestinal protection.
|
Authors | Emma Bateman, Eric Weaver, Gerald Klein, Anthony Wignall, Belinda Wozniak, Erin Plews, Bronwen Mayo, Imogen White, Dorothy Keefe |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 24
Issue 1
Pg. 377-385
(Jan 2016)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 26081596
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents
- Antineoplastic Agents, Phytogenic
- Blood Proteins
- Immunoglobulins
- Irinotecan
- Camptothecin
|
Topics |
- Administration, Oral
- Animals
- Anti-Inflammatory Agents
(administration & dosage, pharmacology)
- Antineoplastic Agents, Phytogenic
(administration & dosage, toxicity)
- Blood Proteins
(administration & dosage, pharmacology)
- Body Weight
(drug effects)
- Camptothecin
(administration & dosage, analogs & derivatives, toxicity)
- Cattle
- Colitis
(chemically induced, prevention & control)
- Diarrhea
(chemically induced)
- Enteritis
(chemically induced, prevention & control)
- Female
- Immunoglobulins
(administration & dosage, pharmacology)
- Injections, Intraperitoneal
- Irinotecan
- Jejunal Diseases
(chemically induced, prevention & control)
- Mucositis
(chemically induced, prevention & control)
- Random Allocation
- Rats
|